Brokers Issue Forecasts for PMVP Q3 Earnings

Key Points

• HC Wainwright forecasts a Q3 2026 loss of $0.25 per share and maintains a Buy rating with a $5.00 price target. Its estimates indicate PMV’s losses could narrow to $1.03 per share in fiscal 2026 and $0.61 in fiscal 2027.
• PMV reported a quarterly loss of $0.34 per share, beating the consensus estimate of a $0.39 loss by $0.05. Analysts collectively rate the stock “Moderate Buy,” with an average price target of $4.33.
• Despite strong institutional ownership of 90.2% and recent new stakes from major investors, PMV remains unprofitable and exposed to the clinical, regulatory, financing, and commercialization risks typical of an early-stage biotechnology company.

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP - Free Report) - Analysts at HC Wainwright issued their Q3 2026 earnings estimates for shares of PMV Pharmaceuticals in a research note issued on Friday, September 4th. HC Wainwright analyst R. Burns forecasts that the company will post earnings of ($0.25) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $5.00 price target on the stock. The consensus estimate for PMV Pharmaceuticals' current full-year earnings is ($1.38) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals' Q4 2026 earnings at ($0.18) EPS, FY2026 earnings at ($1.03) EPS, Q1 2027 earnings at ($0.17) EPS, Q2 2027 earnings at ($0.17) EPS, Q3 2027 earnings at ($0.15) EPS, Q4 2027 earnings at ($0.12) EPS and FY2027 earnings at ($0.61) EPS.

PMV Pharmaceuticals (NASDAQ:PMVP - Get Free Report) last released its quarterly earnings results on Friday, August 14th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.05.

Several other research analysts have also issued reports on the company. Weiss Ratings raised PMV Pharmaceuticals from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Wednesday, August 12th. Oppenheimer lowered their price target on PMV Pharmaceuticals from $6.00 to $5.00 and set an "outperform" rating for the company in a report on Wednesday, May 13th. Finally, LADENBURG THALM/SH SH assumed coverage on PMV Pharmaceuticals in a research note on Wednesday, July 8th. They set a "buy" rating and a $3.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, PMV Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $4.33.

PMV Pharmaceuticals Trading Up 3.9%

Shares of PMVP opened at $1.34 on Wednesday. The firm has a market cap of $71.63 million, a PE ratio of -0.94 and a beta of 1.37. PMV Pharmaceuticals has a 12 month low of $1.02 and a 12 month high of $1.88. The stock has a fifty day moving average price of $1.25 and a 200-day moving average price of $1.30.

Institutional Investors Weigh In On PMV Pharmaceuticals

Large investors have recently made changes to their positions in the stock. Eversept Partners LP purchased a new position in PMV Pharmaceuticals in the 1st quarter worth $2,912,000. Stonepine Capital Management LLC acquired a new stake in PMV Pharmaceuticals during the 2nd quarter worth about $718,355. BlackRock Inc. purchased a new stake in PMV Pharmaceuticals during the 2nd quarter valued at about $1,233,000. Susquehanna International Group LLP purchased a new stake in PMV Pharmaceuticals during the 2nd quarter valued at about $50,000. Finally, ADAR1 Capital Management LLC acquired a new position in shares of PMV Pharmaceuticals in the second quarter valued at about $269,000. 90.20% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting PMV Pharmaceuticals

Here are the key news stories impacting PMV Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating and $5.00 price target, implying substantial upside from PMVP’s recent trading level. The firm forecasts losses of $1.03 per share for fiscal 2026 and $0.61 per share for fiscal 2027, narrower than the current full-year consensus loss estimate of $1.38. Its quarterly projections also show losses declining from $0.25 per share in Q3 2026 to $0.12 per share in Q4 2027, suggesting improving earnings trends. Analysts Set PMV Pharmaceuticals Target Price at $4.33
• Positive Sentiment: PMV Pharmaceuticals appointed Philip Herman as chief commercial officer. The addition of a dedicated commercial leader may signal preparation for future product commercialization and could strengthen investor confidence in the company’s ability to execute if its pipeline advances. PMV Pharmaceuticals Appoints Philip Herman as Chief Commercial Officer
• Neutral Sentiment: Despite the more optimistic outlook, PMV remains unprofitable, with analysts expecting continued quarterly and annual losses. The company’s small market capitalization and early-stage biotechnology profile also leave the stock highly sensitive to clinical, regulatory, financing, and commercialization developments.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function. The company was formerly known as PJ Pharmaceuticals, Inc and changed its name to PMV Pharmaceuticals, Inc in July 2013. PMV Pharmaceuticals, Inc was incorporated in 2013 and is based in Princeton, New Jersey.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.